Nucala (mepolizumab): The power to choose

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg subcutaneously (SC) once every 4 weeks in adults and adolescents 12 years and older. The licenced dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight.1

Don't let patient concerns about administration hold them back.

Nucala (mepolizumab) lyophilised powder Nucala (mepolizumab) lyophilised powder

Nucala is for subcutaneous injection only and should be administered by a healthcare professional. Nucala may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate, and the patient or caregiver are trained in injection techniques.

**Combined primary endpoint analysis of a 12 week, open-label study that assessed the correct use of Nucala pre-filled pen in patients with severe eosinophilic asthma following training on proper pen technique at baseline. The primary endpoint of the study was the proportion of patients who were able to successfully self-administer their observed third dose in-clinic at Week 8 and was determined using a checklist of steps based on instructions for use and visual inspection of the pen (155 of 157 attempted injections). Ease of use was measured through a patient questionnaire at the end of the study using a 5-point scale (not at all, a little, moderately, very, and extremely). Of the patients who successfully self-administered at primary end-point (n= 155), 151 patients completed the questionnaire.2

Please consult the Summary of Product Characteristics for full information on dosing, administration and hypersensitivity reactions.

Dosing and Administration1

  Patients aged 6 to 11 years Patients aged ≥12 years

Pre-filled syringe
Lyophilised powder

Pre-filled pen
Pre-filled syringe
Lyophilised powder


40 mg subcutaneously
every 4 weeks

100 mg subcutaneously
every 4 weeks

Injection site

Caregiver: (syringe) abdomen, thigh or upper arm
Healthcare provider: (syringe/lyophilised powder) abdomen, thigh or upper arm

Self-administration: (pen/syringe) abdomen or thigh
Caregiver: (pen/syringe) abdomen, thigh or upper arm
Healthcare provider: (pen/syringe/lyophilised powder) abdomen, thigh or upper arm

aSecondary endpoint: Rate of clinically significant exacerbations was reduced from 4.25 12 months prior to mepolizumab exposure (n=821) to 1.11 in the 24 months post-exposure (n=820); rate ratio 0.26 (95% CI: 0.24, 0.29); p<0.001.3

bSecondary endpoint: Median maintenance OCS dose reduced from 10.0 mg/day at baseline (n=298) to 0.0 mg/day at 2 years (n=168). The primary endpoint of exacerbation reduction was met. Median maintenance daily OCS dose reduced from 10.0 mg/day (range: 15.0-5.0mg/day) at baseline to 0.0 mg/day at 2 years (range: 5.0-0.0mg/day).3


  1. Nucala SmPC.
  2. Bernstein, D., Pavord, I.D., Chapman, K.R., Follows, R., Bentley, J.H., Pouliquen, I. and Bradford, E., 2020. Journal of Asthma, 57(9), pp.987-998.
  3. Caruso C, Canonica GW, Patel M, et al. International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs. Abstract presented at ERS; 4-6 September 2022; Barcelona, Spain.

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2020 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.

November 2022 | PM-GB-MPL-WCNT-200026 (V4.0)